Skip to main content
    K

    Korro Bio, Inc. (KRRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.71
    -0.90 (-6.61%)

    Market Cap: $186.81M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Korro Bio, Inc. (KRRO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Korro Bio reported revenue of $6.39M for the fiscal year ended Dec 31, 2025, up 181.5% from the year before. That year, net income was -$117.26M with a net margin of -1834.5%, operating cash flow was -$78.56M and free cash flow was -$79.08M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$17.55M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue fell from $28.95M, a compound annual decline of 22.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$6.39M+181.5%100.0%-1906.4%-1834.5%
    Dec 2024$2.27MN/A100.0%-4047.1%-3680.4%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$14.07M-62.0%100.0%-597.3%-602.0%
    Dec 2020$36.98M+27.8%100.0%-74.5%-71.7%
    Dec 2019$28.95MN/A100.0%-71.4%-64.8%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$6.39M$2.27M$0$0$14.07M$36.98M$28.95M$0$0
    Gross profit$6.39M$2.27M$0$0$14.07M$36.98M$28.95M$0$0
    Research and development$65.58M$63.64M$57.25M$42.20M$60.92M$37.41M$18.78M$11.88M$11.97M
    Operating income-$121.86M-$91.91M-$84.53M-$59.00M-$84.03M-$27.55M-$20.68M-$18.94M-$16.31M
    Net income-$117.26M-$83.58M-$81.17M-$58.03M-$84.69M-$26.51M-$18.75M-$19.17M-$20.24M
    EBITDA-$112.83M-$81.66M-$77.59M-$55.66M-$81.53M-$26.32M-$19.72M-$18.29M-$15.78M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$1.29M$1.09M$1.46M$2.55M$2.27M$0$0$0$0
    Gross profit$0$0$0$1.29M$1.09M$1.46M$2.55M$2.27M$0$0$0-$1.75M
    Operating income-$18.46M-$20.11M-$20.44M-$50.40M-$19.24M-$27.20M-$25.02M-$23.04M-$23.29M-$24.13M-$21.45M-$26.89M
    Net income-$17.55M-$18.92M-$19.63M-$50.04M-$18.06M-$25.77M-$23.39M-$21.20M-$21.00M-$21.83M-$19.56M-$25.43M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.67M by $19.15M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$113.51M$226.24M$221.66M$73.74M$185.36M$264.72M$223.22M$44.55M$19.79M
    Current assets$82.37M$131.53M$172.73M$57.08M$134.75M$225.06M$221.35M$42.94M$17.95M
    Cash and equivalents$21.82M$55.64M$166.15M$36.33M$79.64M$220.34M$200.16M$42.19M$17.94M
    Total liabilities$62.07M$65.83M$51.75M$8.91M$54.53M$72.23M$55.86M$4.12M$49.43M
    Short-term debt$2.67M$1.28M$1.99M$2.92M$833.00K$397.00K$1N/AN/A
    Long-term debtN/AN/AN/AN/A$14.17M$15.00M$180.00K$349.00KN/A
    Shareholder equity$51.44M$160.41M$169.91M-$99.03M$130.82M$192.49M$167.36M-$48.28M-$29.64M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$148.12M$163.45M$183.62M$113.51M$161.55M$180.43M$202.21M$226.24M$243.54M$249.59M$197.99M$221.66M
    Total liabilities$59.75M$60.22M$63.99M$62.07M$62.52M$65.32M$63.25M$65.83M$63.91M$51.51M$46.63M$51.75M
    Cash and equivalents$40.22M$24.91M$61.70M$21.82M$24.16M$33.61M$64.14M$55.64M$63.21M$91.15M$138.80M$166.15M
    Shareholder equity$88.37M$103.23M$119.63M$51.44M$99.03M$115.10M$138.96M$160.41M$179.63M$198.08M$151.36M$169.91M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$78.56M-$60.07M-$67.28M-$53.65M-$76.06M-$45.19M$34.22M-$17.02M-$14.61M
    Capital expenditures$518.00K$17.90M$7.84M$5.14M$2.91M$6.67M$1.06M$436.00K$1.86M
    Free cash flow-$79.08M-$77.98M-$75.12M-$58.78M-$78.97M-$51.86M$33.15M-$17.46M-$16.48M
    Investing cash flow$43.99M-$123.35M$11.16M$11.06M-$66.13M$10.40M-$18.26M-$436.00K-$1.86M
    Financing cash flow$685.00K$69.36M$187.76M$18.00K$1.36M$56.69M$142.01M$41.71M$27.98M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$12.94M-$16.99M-$16.07M-$17.70M-$17.18M-$19.23M-$24.45M-$7.50M-$16.09M-$14.59M-$21.89M-$21.11M
    Capital expenditures$27.00K$37.00K$21.00K$84.00K$175.00K$140.00K$119.00K$1.45M$4.88M$5.96M$5.61M$1.66M
    Free cash flow-$12.96M-$17.03M-$16.09M-$17.79M-$17.35M-$19.37M-$24.57M-$8.95M-$20.97M-$20.55M-$27.50M-$22.76M
    Last 12 quarters

    Frequently Asked Questions About KRRO

    What is Korro Bio's annual revenue?

    Korro Bio reported revenue of $6.39M for the fiscal year ended Dec 31, 2025.

    How fast is Korro Bio's revenue growing?

    Revenue was up 181.5% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Korro Bio profitable?

    No. Korro Bio reported net income of -$117.26M for the fiscal year ended Dec 31, 2025, with a net margin of -1834.5%.

    How much free cash flow does KRRO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$78.56M minus capital expenditures of $518.00K produced free cash flow of -$79.08M.

    How much debt does Korro Bio have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.67M and cash and equivalents of $21.82M.